Mutations in type I collagen genes in Japanese osteogenesis imperfecta patients

Pediatrics International

Volumn 49, Issue 5, 2007, Pages 564-569

  Kataoka, Kyoko ^a   Ogura, Eriko ^a   Hasegawa, Kosei ^a   Inoue, Masaru ^b   Seino, Yoshiki ^c   Morishima, Tsuneo ^a   Tanaka, Hiroyuki ^a,d  

^a OKAYAMA UNIVERSITY   (Japan)

^b Japanese Red Cross Okayama Hospital   (Japan)

^c OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^d NONE   (Japan)

Author keywords

Denaturing HPLC; Gene analysis; Osteogenesis imperfecta (OI)

Indexed keywords

COLLAGEN TYPE 1;

AMPLICON; ARTICLE; CLINICAL ARTICLE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; FEMALE; GENE DELETION; GENE INSERTION SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENOMICS; HETERODUPLEX ANALYSIS; HUMAN; INTRON; MALE; OSTEOGENESIS IMPERFECTA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLLAGEN TYPE I; EXONS; HUMANS; INTRONS; JAPAN; MUTATION; OSTEOGENESIS IMPERFECTA; POLYMERASE CHAIN REACTION;

EID: 34548692976     PISSN: 13288067     EISSN: 1442200X     Source Type: Journal    
DOI: 10.1111/j.1442-200X.2007.02422.x     Document Type: Article

References (24)

1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 1979 16 : 101 16.
2. Glorieux FH, Bishop NJ, Plotkin H et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 1998 339 : 947 52.
3. Xiao W, Oefner PJ. Denaturing high-performance liquid chromatography: A review. Hum. Mutat. 2001 17 : 439 74.
4. Korkko J, Ala-Kokko L, De Paepe A et al. Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: Identification of common sequences of null-allele mutations. Am. J. Hum. Genet. 1998 62 : 98 110.
5. Pace JM, Atkinson M, Willing MC et al. Deletions and duplications of Gly-Xaa-Yaa triplet repeats in the triple helical domains of type I collagen chains disrupt helix formation and result in several types of osteogenesis imperfecta. Hum. Mutat. 2001 18 : 319 26.
6. Wang Q, Orrison BM, Marini JC. Two additional cases of osteogenesis imperfecta with substitutions for glycine in the alpha 2(I) collagen chain. A regional model relating mutation location with phenotype. J. Biol. Chem. 1993 268 : 25 162 7.
7. Ravnik-Glavac M, Atkinson A, Glavac D et al. DHPLC screening of cystic fibrosis gene mutations. Hum. Mutat. 2002 19 : 374 83.
8. Hartikka H, Kuurila K, Korkko J et al. Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients. Hum. Mutat. 2004 24 : 147 54.
9. Ries-Levavi L, Ish-Shalom T, Frydman M et al. Genetic and biochemical analyses of Israeli osteogenesis imperfecta patients. Hum. Mutat. 2004 23 : 399 400.
10. Ward LM, Lalic L, Roughley PJ et al. Thirty-three novel COL1A1 and COL1A2 mutations in patients with osteogenesis imperfecta types I-IV. Hum. Mutat. 2001 17 : 434.
11. Gat-Yablonski G, Ries L, Lev D et al. A missense mutation in ColA1 in Jewish Israeli patient with mild osteogenesis imperfecta, detected by DGGE. Hum. Genet. 1997 101 : 22 5.
12. Primorac D, Rowe DW, Mottes M et al. Osteogenesis imperfecta at the beginning of bone and joint decade. Croat. Med. J. 2001 42 : 393 415.
13. Yamanoshita O, Kubota T, Hou J et al. DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. Int. J. Cancer 2005 114 : 74 9.
14. Young J, Barker M, Fraser L et al. Mutation searching in colorectal cancer studies: Experience with a denaturing high-pressure liquid chromatography system for exon-by-exon scanning of tumour suppressor genes. Pathology 2002 34 : 529 33.
15. Bunn CF, Lintott CJ, Scott RS et al. Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Hum. Mutat. 2002 19 : 311.
16. Arnold N, Gross E, Schwarz-Boeger U et al. A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. Hum. Mutat. 1999 14 : 333 9.
17. Di Lullo GA, Sweeney SM, Korkko J et al. Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J. Biol. Chem. 2002 277 : 4223 31.
18. Cabral WA, Chernoff EJ, Marini JC. G76E substitution in type I collagen is the first nonlethal glutamic acid substitution in the alpha1(I) chain and alters folding of the N-terminal end of the helix. Mol. Genet. Metab. 2001 72 : 326 35.
19. Cabral WA, Makareeva E, Colige A et al. Mutations near amino end of alpha 1(I) collagen cause combined osteogenesis imperfecta/Ehlers-Danlos syndrome by interference with N-propeptide processing. J. Biol. Chem. 2005 280 : 19 259 69.
20. Lund AM, Jensen BL, Nielsen LA et al. Dental manifestations of osteogenesis imperfecta and abnormalities of collagen I metabolism. J. Craniofac. Genet. Dev. Biol. 1998 18 : 30 37.
21. Rose NJ, Mackay K, Byers PH et al. A Gly238Ser substitution in the alpha 2 chain of type I collagen results in osteogenesis imperfecta type III. Hum. Genet. 1995 95 : 215 18.
22. Nuytinck L, Wettinck K, Freund M et al. Osteogenesis imperfecta phenotypes resulting from serine for glycine substitutions in the alpha2(I) collagen chain. Eur. J. Hum. Genet. 1997 5 : 161 7.
23. Pepin M, Atkinson M, Starman BJ et al. Strategies and outcomes of prenatal diagnosis for osteogenesis imperfecta: A review of biochemical and molecular studies completed in 129 pregnancies. Prenat. Diagn. 1997 17 : 559 70.
24. Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta: Clinical and molecular diversity. Eur. Cell Mater. 2003 5 : 41 7.